DRG Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NSCLC for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s NSCLC forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with NSCLC per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with NSCLC per year?
  • How will improvements in survival change the number of first-line drug-treatment opportunities for NSCLC?
  • How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for NSCLC?
  • Of all people diagnosed with NSCLC, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NSCLC over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following NSCLC subpopulations:

  • Diagnosed incident cases: adenocarcinoma by ALK translocation status.
  • Diagnosed incident cases: adenocarcinoma by EGFR translocation status.
  • Diagnosed incident cases: adenocarcinoma by KRAS mutation status.
  • Diagnosed incident cases: adenocarcinoma by stage and resection status.
  • Diagnosed incident cases: NSCLC by ALK translocation status.
  • Diagnosed incident cases: NSCLC by EGFR mutation status.
  • Diagnosed incident cases: NSCLC by KRAS mutation status.
  • Diagnosed incident cases: squamous NSCLCby stage and resection status.
  • Diagnosed incident cases:NSCLCunverified by stage at diagnosis.

Note: Coverage may vary by country.

Table of contents

  • Non-Small-Cell Lung Cancer - Epidemiology - Middle East & Africa

Author(s): Lade Ayodele; Nicole Zhang, MPH

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets.

Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a Ph.D. in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.

Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders.

She holds an M.P.H. from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a B.A. in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.


Related Reports

Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers.

View Details

Non-Small-Cell Lung Cancer - Current Treatment - Detailed, Expanded Analysis (EU5) - 2020

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has r...

View Details

Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Squamous NSCLC (US/EU)

The preferred initial treatment for metastatic squamous non-small-cell lung cancer (NSCLC), regardless of PD-...

View Details

Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer | China In-Depth | China

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...

View Details